NeoGenomics is a sponsor of ASCO Direct™ Hawaii! Make plans to come by our booth and learn about our oncology solutions for solid tumor patients, hematological cancers, and more. We’ll see you July 13 and 14 at the ‘Alohilani Resort Waikiki Beach in Honolulu, Hawaii.
NeoGenomics Laboratories’ Post
More Relevant Posts
-
Tamoxifen is a selective estrogen receptor modulator (SERM) commonly used to treat estrogen receptor-positive breast cancer in both pre- and post-menopausal women.
Tamoxifen
To view or add a comment, sign in
-
Always great to talk to Jeff about the vision and journey of CancerLinQ®, founded by American Society of Clinical Oncology (ASCO) and now an initiative of ConcertAI - Robert Miller https://lnkd.in/dDfy7nP3 #oncodaily #oncology #cancer #technology #data #AI #precisiononcology #RWD #CancerResearch #oncologydata
To view or add a comment, sign in
-
One of our co-founders, Dr Nina Fuller-Shavel, has recently published a review on integrative oncology approach to supporting immune checkpoint inhibitors with one of our expert panel members, Dr Jon Krell. We are preparing some materials to help people on ICI therapy learn key points of the article below with a helpful graphical overview, and we look forward to releasing this later in the month. https://lnkd.in/gqJt_Bx5 #immunotherapy #integrativeoncology #cancersupport #cancercare #lifestylemedicine
To view or add a comment, sign in
-
-
The Cutaneous Oncology Program at Washington University School of Medicine in St. Louis, co-led by Ryan Fields, MD, George Ansstas, MD, and Lynn Cornelius, MD, will soon be able to administer tumor-infiltrating lymphocyte (TIL) therapy for certain adult patients with metastatic melanoma, an aggressive skin cancer that has spread to other parts of the body, after the therapy recently received approval from the Food and Drug Administration. Learn more about the team's work at Siteman Cancer Center, how the therapy will help those with melanoma, and how this therapy may be applied in other settings in the future: https://lnkd.in/dPvR_Z5a
To view or add a comment, sign in
-
-
At #AACR24, look out for new data on the clinical utility of our Methylation Platform across the cancer continuum and the impact of multi-cancer early detection testing. The new data will highlight the potential of our targeted Methylation Platform across early detection and precision oncology settings. See the details here, including three oral presentations from GRAIL: https://lnkd.in/dPSD9Zf2
To view or add a comment, sign in
-
-
Evaluating the Impact of Metastatic Breast Cancer on Patients: An expert panel discusses the clinical and economic impact of metastatic breast cancer (mBC) on patients, the prognosis for those with mBC, the three FDA-approved CDK4/6 inhibitors for HR+/HER2- mBC, and the importance of overall survival as a clinical trial endpoint and its relevance to clinical practice. #finance #pharmacy #lifesciences
Evaluating the Impact of Metastatic Breast Cancer on Patients
pharmacytimes.com
To view or add a comment, sign in
-
1 in 5 breast cancer patients will develop lymphedema, leading to complex and lifelong challenges. Early detection using Bioimpedance Spectroscopy (BIS) can make a significant difference. Discover how a prospective Lymphedema Surveillance Program can support your practice in improving patient outcomes. Learn more about the impact of early intervention and how BIS technology can help prevent chronic BCRL. 🔗https://ow.ly/9Gl050T00yc #BCRL #LymphedemaPrevention #EarlyDetection #BreastCancerCare
Lymphedema Prevention Program
impedimed.com
To view or add a comment, sign in
-
New Series Alert! Kirollos Hanna, PharmD, BCPS, BCOP, FACCC, leads a panel discussion about CDK4/6 inhibitor use in high-risk early breast cancer with experts Naomi Dempsey, MD; Joyce O'Shaughnessy, MD; and Hope S. Rugo, MD, FASCO. Tune in to learn about trial updates, best practices in managing toxicity profiles, and financial challenges to navigate while optimizing patient outcomes. Watch here: https://bit.ly/4eGWTru #BreastCancer #ManagedCare
Advances in CDK4/6 Inhibitor Use in High-Risk Early Breast Cancer: 2024 Updates
ajmc.com
To view or add a comment, sign in
-
Exciting News from Carevive: Elevating Patient Experience in Oncology Research! Our Real-World Evidence (RWE) team, alongside our esteemed partners, recently showcased groundbreaking posters at prestigious conferences including ISPOR, ASCO, ASCO Quality, and ASH. These presentations, the culmination of collaborative efforts with leading academic institutions, underscore our commitment to advancing oncology research. We're proud to announce a significant milestone: the publication of three posters in collaboration with Takeda, shedding light on the patient experience in various hematologic malignancies. These publications mark our inaugural joint endeavors with industry, reinforcing our dedication to impactful partnerships. At Carevive, our mission to spearhead patient experience data in oncology remains unwavering. As we continue to build our 2024 collection, we invite you to explore our 2023 repository of publications and posters. https://lnkd.in/eceMxc3x Aaron Galaznik Keri Collette Mordecai Kramer Emelly Rusli Bruno Lempernesse Nadia Still DNP, RN April Boyd #carevive #digitaloncology #cancer #cancercare #oncology #patientreportedoutcomes #oncologydata #clinicalinnovation #drugcommercialization #RWD #RWE #smartdata
Invaluable Oncology Insights About the Patient Experience in Cancer Care
https://www.carevive.com
To view or add a comment, sign in
-
Inside Sales Manager-CRO-Changing the present;"Every great advance in science has issued from a new audacity of the imagination." John Dewey #fortreaforward #experiencematters
Fortrea's expert panel will explore the current and future landscape of these CAR-T therapy, highlighting its diverse applications and potential. From revolutionizing treatment approaches in non-oncological diseases to leveraging operational oncology experience for broader therapeutic insights, this webinar will provide valuable lessons and insights into the transformative power CAR-T therapy across various therapeutics.
Register for this webinar to gain insights into the adaptation of CAR-T therapy to various non-oncologic conditions. The focus is on the seamless transition of oncology expertise into non-oncological realms, illustrating how clinical development and operational insights gleaned from managing cancer treatments can be effectively applied to enhance patient care in other disease contexts. Wednesday, June 19, 2024 | 11am EDT (NA) / 4pm BST (UK) / 5pm CEST (EU-Central) https://lnkd.in/e2uAvDXC
To view or add a comment, sign in
-
Founder @ Mirana | Fractional CRO & Advisor | Expert in Provider, HCO, Lab & Patient Data | 15+ Years Experience in Oncology Diagnostics & Precision Medicine
1moI am sure there was no lack of volunteers to work this event! 🤣